Triple-negative breast carcinoma

This early-phase trial tests an experimental vaccine made from the alpha-lactalbumin protein, found in breast tissue, to see if it can safely train the immune system to fight triple-negative breast cancer cells. The study enrolls people who have completed treatment for non-metast…

Researchers are testing whether adding the immunotherapy drug tislelizumab to standard TAC chemotherapy helps shrink triple-negative breast cancer before surgery. The trial enrolls 36 women with newly diagnosed triple-negative breast cancer. Participants receive six cycles of tis…

This early-stage trial is testing a new drug called tuvusertib, given together with either lartesertib or avelumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see how the body pr…

This study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy (carboplatin) helps people with metastatic triple-negative breast cancer live longer without their disease getting worse. About 78 participants with advanced cancer that has spread will rece…

This trial tests an experimental drug called FLX475, given alone or with the immunotherapy pembrolizumab, in people with advanced cancers that have not responded to standard treatments. The study aims to find the safest dose and to see whether the combination can shrink tumors. P…

This phase 2 study tests a new drug called SKB264, alone or with another drug KL-A167, in 175 people with advanced HER2-negative breast cancer that hasn't been treated before. The goal is to see if the combination is safe and can shrink tumors. Participants are split into groups …

This phase II trial is testing whether adding an experimental drug called BEBT-209 to standard chemotherapy (carboplatin and gemcitabine) can help people with advanced triple-negative breast cancer. The study will enroll about 65 women whose cancer has returned or spread and is n…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can eliminate all signs of cancer in people with early-stage triple-negative breast cancer before they have surgery. About 31 participants with small tumors (1 to 2.5 cm) that haven't sp…

This study tests whether adding the drug ruxolitinib to standard chemotherapy can help treat triple-negative inflammatory breast cancer, a rare and aggressive form of breast cancer. About 23 adults with this diagnosis will receive the combination before surgery. The goal is to se…

This phase 2 trial is testing whether a combination of two chemotherapy drugs (nab-paclitaxel and cisplatin) plus an immunotherapy drug (camrelizumab) can help people with metastatic triple-negative breast cancer live longer without their disease getting worse. The study enrolls …

This early-phase trial tests a new drug called PEP-010 in people with advanced solid tumors that have spread. The study checks if PEP-010 is safe alone or with chemotherapy (paclitaxel or gemcitabine). About 57 adults with metastatic pancreatic, ovarian, or other solid cancers wi…

This phase 2 trial tested whether adding carboplatin and/or bevacizumab to standard chemotherapy before surgery helps shrink tumors in people with a hard-to-treat type of breast cancer (hormone receptor-poor, HER2-negative, including triple-negative). 454 participants received we…

This phase II trial studied 92 women with early-stage breast cancer to see how well chemotherapy (paclitaxel and cyclophosphamide) with or without trastuzumab works before surgery. The main goals were to check side effects and see if the tumor disappears completely by the time of…

This study tested a new drug called CT7001, alone or with other cancer treatments, in 124 people with advanced solid tumors like breast and prostate cancer. The main goal was to check safety and side effects. The drug is taken by mouth and aims to control the disease, not cure it…

This phase II trial tested whether combining the immunotherapy drug pembrolizumab (Keytruda) with the chemotherapy carboplatin could help people with HER2-negative metastatic breast cancer that has spread. The 12 participants had cancer cells in their blood and had already tried …

This early-phase study tested a personalized cancer vaccine (RO7198457) in 273 patients with advanced solid tumors like melanoma, lung, and breast cancer. The vaccine was given alone or with an immunotherapy drug (atezolizumab) to see if it was safe and how the body responded. Th…

This study tested a new drug called nadunolimab, which blocks a protein that helps cancer grow, combined with standard chemotherapy for people with advanced triple-negative breast cancer. The trial had two parts: first to find a safe dose, then to see if the combination shrinks t…

This phase 2 study tested a drug called patritumab deruxtecan in 121 people with advanced or metastatic breast cancer. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The main goal was to see how many patients had their tumors shr…

This study tested a combination of enzalutamide (a hormone blocker) and paclitaxel (chemotherapy) given before surgery to 24 people with a specific type of triple-negative breast cancer that has androgen receptors. The goal was to see if this treatment could shrink tumors and red…

This study tested a combination of two drugs, lenvatinib and pembrolizumab, in 611 people with advanced cancers like breast, ovarian, stomach, colorectal, brain, bile duct, or pancreatic cancer that had stopped responding to standard treatments. The goal was to see if the combo c…

This early-phase trial tested a new drug called AZD8186 combined with the chemotherapy docetaxel in 23 patients with advanced solid tumors that have PTEN or PIK3CB gene mutations. The main goal was to find the safest dose and understand side effects. The study is complete, but re…

This study tested a combination of the immunotherapy drug atezolizumab and precise radiation (stereotactic radiosurgery) in 6 people with triple-negative breast cancer that had spread to the brain. The goal was to see if the combo could slow or stop the cancer from growing. The t…

This phase 3 trial tested whether adding the immunotherapy drug toripalimab to standard chemotherapy (nab-paclitaxel) helps people with metastatic or recurrent triple-negative breast cancer live longer without their cancer growing. The study included 531 participants and compared…

This phase 2 trial tested whether adding the drug veliparib to standard chemotherapy (cisplatin) helps people with metastatic triple-negative or BRCA-related breast cancer, including those with brain metastases. The study enrolled 344 participants to see if the combination slows …

This study tested a new drug called STRO-002 in 19 Chinese adults with advanced ovarian, endometrial, or other solid tumors that had not responded to prior treatments. STRO-002 is an antibody-drug conjugate, meaning it combines a targeted antibody with a chemotherapy drug to deli…

This completed phase 2 trial tested a combination of sintilimab (an immunotherapy), anlotinib (a drug that blocks blood vessel growth), and standard chemotherapy in 29 people with early-stage triple-negative breast cancer. The treatment was given before surgery to shrink or elimi…

This study tested leflunomide, a pill usually used for arthritis, in 17 women with metastatic triple negative breast cancer (a fast-growing type). The goal was to see if it is safe and can help control the cancer. The drug works by blocking a protein the cancer needs to grow.

This early study tested the safety of an experimental drug called MK-4700, given alone or with the approved immunotherapy Keytruda, in 5 people with advanced solid tumors that had stopped responding to other treatments. The main goal was to find a safe dose and see how the body h…

This study looked at whether a test called RAD51-foci can predict how well the drug olaparib works in people with advanced HER2-negative breast cancer who have certain gene mutations (BRCA1, BRCA2, PALB2, RAD51C, or RAD51D). About 65 participants received olaparib, and researcher…

This first-in-human trial tested personalized RNA vaccines designed to target each patient's unique tumor mutations in triple negative breast cancer (TNBC). 42 participants received two custom-made vaccines to stimulate their immune system. The main goal was to check safety and t…

This study tested a combination of two drugs—NT-I7 (efineptakin alfa) and pembrolizumab (Keytruda)—in 215 people with advanced solid tumors that had stopped responding to treatment. The goal was to check safety, find the right dose, and see if the combo could shrink tumors. The t…

This study tested whether injecting a modified herpes virus (T-VEC) directly into tumors, alongside standard chemotherapy before surgery, could better eliminate triple negative breast cancer. The virus is designed to infect and destroy cancer cells while leaving healthy cells alo…

This study tested a combination of chemotherapy (nab-paclitaxel) and immunotherapy (atezolizumab) given before surgery to women with triple-negative breast cancer. The goal was to shrink tumors and reduce the amount of breast tissue that needs to be removed. The trial involved 37…

This study tested a specific chemotherapy combination given before surgery for people with triple-negative breast cancer. The goal was to see if the treatment could completely eliminate the cancer from the breast and lymph nodes. 29 participants received the drugs, and the main o…

This early-phase study tested a new treatment called PRGN-3007 UltraCAR-T cells in 3 adults with advanced blood cancers (like leukemia and lymphoma) or triple-negative breast cancer. The goal was to find a safe dose and see if the therapy can shrink tumors. The study is now compl…

This study tested a new drug called RP-6306 in 28 people with advanced cancer that could not be cured. The goal was to see if adding RP-6306 to standard treatment helps shrink tumors and is safe. Researchers also looked for specific biomarkers to see if some patients respond bett…

This early-stage trial tested a new oral drug, MSP008-22, in 7 adults with advanced solid tumors (breast, ovarian, prostate, head and neck cancers) that had spread or could not be removed. The main goal was to find a safe dose and check for side effects. This is a first step to s…

This pilot study tested a combination of two drugs, veliparib and lapatinib, in 20 people with metastatic triple negative breast cancer that had already been treated. The main goal was to see how safe the combination is and how many patients respond. All participants received the…

This study tested an experimental drug called RC88 in 198 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors or slow their growth. The study was completed and looked at sid…

This phase 1 study tested an experimental drug called LY3039478 in 247 people with advanced or metastatic cancer, including lymphoma. The main goal was to find a safe dose and see how the drug affects the body. Researchers also looked for signs that the drug might shrink tumors.

This study tested the safety of combining the immunotherapy drug atezolizumab with the chemotherapy nab-paclitaxel in 184 people with advanced triple-negative breast cancer that had spread. Participants had not received prior chemotherapy for their advanced disease. The main goal…

This study tested a new drug (TJ004309) combined with an approved immunotherapy (atezolizumab) in 25 people with advanced ovarian, head and neck, lung, gastrointestinal, or triple-negative breast cancers. The goal was to see if the combination could shrink tumors. Participants ha…

This Phase 3 trial tested whether the immunotherapy drug avelumab, given after standard treatments like surgery and chemotherapy, can help prevent breast cancer from coming back in people with high-risk triple negative breast cancer. The study enrolled 474 participants who had al…

This study tested a combination of two drugs, ladiratuzumab vedotin and pembrolizumab, in 185 people with advanced triple-negative breast cancer that had spread. The main goals were to check for side effects and see how well the drugs shrank tumors. The trial was completed and pr…

This early-stage study tested the safety of combining the drug rucaparib with standard radiation therapy in 31 women with triple-negative breast cancer who still had cancer cells after chemotherapy and surgery. The goal was to find a safe dose and see if the combination could be …

This study tested a new immune-boosting treatment called IRX-2 in 16 people with early stage breast cancer. The goal was to see if giving IRX-2 before chemotherapy is safe and helps the immune system fight the tumor. The treatment was given before surgery, and researchers looked …

This phase 2 trial tested whether adding loperamide (Imodium) and a white blood cell booster (G-CSF) could reduce severe diarrhea and low white blood cell counts caused by the drug Trodelvy in people with advanced breast cancer. Fifty patients with metastatic triple-negative or l…

This early-phase trial tested a new drug called CyPep-1, injected directly into tumors, combined with the immunotherapy pembrolizumab (Keytruda) in 6 people with advanced head and neck cancer, melanoma, or triple-negative breast cancer. The main goal was to check safety and side …

This early-stage trial tested the drug olaparib (a PARP inhibitor) given alongside radiation therapy for people with triple-negative breast cancer that is advanced or has come back. The main goal was to find the safest dose of olaparib when used with radiation, and to watch for s…

This phase 3 trial tested whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps people with triple-negative breast cancer that has returned within 12 months of initial treatment. The study enrolled 595 participants and compared survival outcomes betwee…

This phase II trial tested a combination of panitumumab (a targeted therapy) plus two chemotherapy drugs (carboplatin and paclitaxel) given before surgery to women with triple-negative breast cancer that didn't respond to standard chemo. The goal was to shrink tumors and reduce t…

This early-phase study tested a new drug called boserolimab (MK-5890), either alone or combined with the immunotherapy pembrolizumab (KEYTRUDA), in 182 adults with advanced solid tumors, including lung and breast cancers. The main goals were to check safety and how the drug moves…

This study tested a combination of two drugs, crizotinib and fulvestrant, in 33 people with advanced lobular breast cancer that had lost a protein called E-cadherin. It also tested crizotinib alone in people with diffuse gastric cancer, triple-negative lobular breast cancer, or o…

This study tested whether adding the drug pembrolizumab to standard chemotherapy helps people with triple negative breast cancer. Over 1,100 participants received either pembrolizumab or a placebo with chemo before surgery, then continued the study drug after surgery. The goal wa…

This early-phase study tested an experimental drug (MK-1454) injected directly into tumors, either alone or with pembrolizumab (Keytruda), in 156 people with advanced solid tumors or lymphomas. The main goals were to find the safest dose and check for side effects. The study also…

This early-phase study tested a new antibody called HMBD-002, given alone or with pembrolizumab, in 48 adults with advanced solid tumors (like lung or breast cancer) that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, and s…

This early-phase trial tested whether the drug bexarotene (Targretin) could make chemotherapy-resistant triple-negative breast cancer cells sensitive to chemo again. Twelve women with metastatic, taxane-resistant breast cancer took bexarotene pills plus capecitabine (Xeloda) chem…

This early study tested a combination of a modified herpes virus (T-VEC) and an immunotherapy drug (atezolizumab) in 28 women with aggressive breast cancer that did not fully disappear after standard chemotherapy. The virus was injected directly into tumors to kill cancer cells a…

This early-phase trial tested an experimental drug called TAK-676 combined with the immunotherapy pembrolizumab after radiation therapy in 34 adults with advanced lung, breast, or head/neck cancers that had stopped responding to checkpoint inhibitors. The main goals were to check…

This study tested a new radioactive tracer called 89Zr-TLX250 for PET scans in 12 people with metastatic triple negative breast cancer. The goal was to see if it could find more tumors than the standard FDG PET scan, especially in the brain. Researchers compared the number of les…

Researchers want to learn which molecules on cancer cells the immune system attacks when checkpoint inhibitor drugs work well. They collect tumor and blood samples from adults with solid tumors who respond to these drugs, either during treatment or after surgery. The team then se…

Researchers are pooling data from 3,648 women with early triple-negative breast cancer who received dose-dense sequential chemotherapy in seven studies. They will analyze tumor tissue and germline DNA to see how genetic and clinical features relate to long-term overall survival. …

This study looks back at medical records of women with triple-negative breast cancer who had chemotherapy and radiation before surgery. It focuses on those who still had cancer cells left after treatment (residual disease) and tracks how long they lived without the cancer coming …

This study investigates whether tumor DNA found in the blood (called plasma tumor DNA or ptDNA) can predict how well breast cancer responds to chemotherapy given before surgery. Researchers will collect blood samples from 228 people with early-stage, high-risk breast cancer (HER2…

This study looked at whether women with early-stage breast cancer benefit from having a breast MRI in addition to standard mammograms before surgery. Researchers tracked 319 women to see if the MRI helped reduce the chance of cancer coming back, lowered the need for repeat surger…

This study tested three types of messages to encourage genetic testing in 1,283 people at risk for hereditary breast and ovarian cancer. Participants received an electronic health record message, then a text message, then a doctor's reminder if needed. The goal was to see which a…

This study looked at whether the types of bacteria in the gut and inside tumors affect how well chemotherapy works in triple negative breast cancer. Researchers followed 49 patients receiving standard chemotherapy before surgery. They collected samples to see if certain bacteria …

This completed study looked at over 1,500 women with early-stage HER2-positive or triple-negative breast cancer who had no signs of cancer in their lymph nodes on ultrasound. All had breast-conserving surgery with lymph node removal. The goal was to see how often cancer actually …

This study tested two chemotherapy drugs, cisplatin and paclitaxel, given before surgery to 147 women with triple negative breast cancer. The goal was to see if a genetic test called HRD could predict which drug would work better. Researchers measured how much the tumor shrank af…

This study aimed to create a communication tool to help doctors and patients discuss when cancer stops responding to treatment. Researchers interviewed 128 people, including patients with certain breast cancers, metastatic uveal melanoma, parents of children with cancer, and heal…